HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.95
+0.09 (+4.84%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.86
Open1.83
Bid1.65 x 3000
Ask2.39 x 1100
Day's Range1.83 - 2.02
52 Week Range1.64 - 5.64
Volume16,409
Avg. Volume47,271
Market Cap22.849M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

    IRVINE, Calif., Nov. 13, 2018 -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health,.

  • GlobeNewswirelast month

    Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has entered into a Sponsored Research Agreement with Texas Heart Institute for the development of HJLI’s CoreoGraft®, an off the shelf conduit intended to be used for coronary artery bypass surgery. Founded in 1962 by world renowned cardiovascular surgeon Dr. Denton A. Cooley, the Texas Heart Institute is recognized internationally for research programs in cardiology, cardiovascular surgery, stem cell and gene therapy, and regenerative medicine, and is dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education and improved patient care.

  • GlobeNewswire2 months ago

    Hancock Jaffe Appoints Three New Independent Directors

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has appointed accomplished medical device professionals Dr. Francis Duhay and Dr. Sanjay Shrivastava, and recognized fund manager and equity analyst Marc W. Robins, CFA to its board of directors, effective as of October 2, 2018. Dr. Francis Duhay, a trained cardiac and thoracic surgeon, is the former Chief Medical Officer at Edwards Life Sciences, the world’s leader in heart valves, where he led medical and clinical affairs for transcatheter and surgical heart valves.  While at Edwards, Dr. Duhay led the preparation and submission, and ultimate regulatory approval of two FDA Premarket Approval (PMA) applications for transcatheter and surgical heart valve therapies and was responsible for the design and execution of the applicable clinical trials.  Dr. Duhay was also the Vice President and General Manager of the Ascendra™ transcatheter heart valve business unit at Edwards, where he grew the unit from sixteen to eighty employees and contributed to annual growth in sales from $3 million to $250 million.  Dr. Duhay was also an industry representative and clinical expert, and member of the working group for ISO 5840, the international quality standard for the design, development, and testing of heart valves.

  • GlobeNewswire2 months ago

    Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that it will present and meet with potential investors at The MicroCap Conference on October 1 and 2 at The Essex House in New York City. HJLI’s presentation will take place at 10:00 am EDT on Tuesday, October 2.  Interested investors should register for the conference at www.microcapconf.com, or should contact the company directly to request a meeting. HJLI is currently waiting for approval from INVIMA, the Colombian equivalent of the US FDA, to begin its first-in-human trial for the Company’s VenoValve®, a medical device designed to treat severe cases of Chronic Venous Insufficiency (“CVI”).  Severe CVI occurs when valves in the deep venous system of the leg malfunction, causing blood to pool in the lower extremities.

  • Simply Wall St.2 months ago

    What Investors Should Know About Hancock Jaffe Laboratories Inc’s (NASDAQ:HJLI) Financial Strength

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Hancock Jaffe Laboratories Inc (NASDAQ:HJLI), as the company does not have to adhere to strict debt covenants. However, it also Read More...

  • GlobeNewswire2 months ago

    Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has completed and submitted its application to INVIMA (the Colombian equivalent of the US FDA) for approval of its first-in-human trial for the VenoValve®.  INVIMA is the last regulatory approval that HJLI needs in order to begin its first-in-human testing in Colombia. HJLI expects to receive a response from INVIMA within 60 days. In order to facilitate the INVIMA application process and its first-in-human trial in Columbia, HJLI has hired Bioaccess™, a U.S. based contact research organization (CRO) that specializes in obtaining regulatory approval and in facilitating clinical trials in Colombia.

  • GlobeNewswire2 months ago

    Diamond Equity Research Initiates Coverage on Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) with a Valuation of $6.60 Per Share

    NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies, has initiated coverage of Hancock Jaffe Laboratories, Inc. (HJLI). Hancock Jaffe is developing three promising cardiac and vascular product candidates (CoreoGraft, VenoValve, and a Bio-prosthetic Heart Valve), targeting an enormous combined market of $53 billion in the U.S. alone. With HJLI’s products potentially delivering better patient outcomes than available treatments, the company possessing extensive experience with proprietary tissue processing and manufacturing methodologies, strong intellectual property, and an experienced senior management team, we view Hancock Jaffe as a unique small capitalization investment opportunity.

  • GlobeNewswire2 months ago

    Hancock Jaffe to Present at Fourth Annual Robins Equity Research Roundup Conference

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it will present at the Fourth Annual Robins Equity Research Roundup, September 24, 25, and 26 in Portland, Oregon. The Robins Equity Research Roundup features a select group of up and coming public and private companies and attracts professional money managers and high net worth investors. The conference is hosted by Marc Robins, a well-known fund manager, publisher, and former equity analyst who has a large following among the micro-cap investors.

  • GlobeNewswire2 months ago

    New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve®

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, has commissioned a research report from The Sage Group, a research organization specializing in peripheral vascular disease. The report, titled “Chronic Venous Disease: Epidemiology and Economics” analyzes the size of the addressable market for HJLI’s VenoValve, as well as the economic burden of Chronic Venous Insufficiency (CVI). The report looks at the prevalence in the U.S. of other chronic diseases such as Alzheimer’s, Stroke, Cancer, Coronary Heart Disease, Peripheral Artery Disease, and Diabetes and compares them to CVI.

  • GlobeNewswire2 months ago

    Hancock Jaffe Laboratories’ VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders as a Future Option for Treating Deep Vein Disease

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that the Journal of Vascular Surgery Venous and Lymphatic Disorders published an article on present and future options for treating deep vein disease, which features the company’s VenoValve® implant.   The Journal of Vascular Surgery Venous and Lymphatic Disorders is the official peer-reviewed journal of the Society for Vascular Surgery and the American Venous Forum.  HJLI expects to begin first-in-human testing of the VenoValve in late 2018.

  • ACCESSWIRE5 months ago

    Hancock Jaffe Laboratories (HJLI) Stock: A Flagship Product That Should Not Be Ignored!

    CORAL SPRINGS, FL / ACCESSWIRE / June 5, 2018 / The biotechnology space is one that's booming, with innovation seemingly around every corner. Nonetheless, even with all of the innovation taking place, ...